Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Schizophrenia

Free Subscription Articles published in Neuropsychopharmacology Retrieve available abstracts of 60 articles: HTML format

Single Articles

July 2026
1. GATTUSO JJ, Kamal A, Payet JM, Havaux K, et al
   Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.
   Neuropsychopharmacology. 2026 Jul 18. doi: 10.1038/s41386-026-02501.
   PubMed     Abstract available
   
   
   
2. KWON SH, Martinowich K
   Neuronal genetic risk within the multicellular landscape of schizophrenia.
   Neuropsychopharmacology. 2026 Jul 10. doi: 10.1038/s41386-026-02497.
   PubMed    
   
   
   
3. HINDLEY G, Mizuno Y, Beck K, Carreira Figueiredo I, et al
   Does a monoclonal antibody targeting immune cells affect glutamatergic level in schizophrenia? A multimodal PET/MRS brain imaging study.
   Neuropsychopharmacology. 2026 Jul 9. doi: 10.1038/s41386-026-02466.
   PubMed     Abstract available
   
   
   
4. TRAYVICK J, Perlman G, Jonas KG, Donaldson KR, et al
   Auditory event-related potentials and psychosis dimensions.
   Neuropsychopharmacology. 2026 Jul 4. doi: 10.1038/s41386-026-02487.
   PubMed     Abstract available
   
   
   June 2026
5. MAYER MR, Choo TH, Javitt DC, Kantrowitz JT, et al
   Serotonin type 3 receptor (5-HT(3)R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis.
   Neuropsychopharmacology. 2026 Jun 17. doi: 10.1038/s41386-026-02467.
   PubMed     Abstract available
   
   
   
6. PARKER N, Koch E, Shadrin AA, Fuhrer J, et al
   Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.
   Neuropsychopharmacology. 2026;51:1300-1309.
   PubMed     Abstract available
   
   
   April 2026
7. CHANG X, Bryant L, Mena Ortega S, Howes O, et al
   A frontotemporal dementia-like phenotype in schizophrenia: links to striatal dopamine and iron accumulation.
   Neuropsychopharmacology. 2026 Apr 25. doi: 10.1038/s41386-026-02426.
   PubMed     Abstract available
   
   
   
8. KHIN NA, Fan RH, Ge T, Klein HS, et al
   A phase 2 randomized controlled trial of luvadaxistat in treatment of adults with cognitive impairment associated with schizophrenia: results from the ERUDITE study.
   Neuropsychopharmacology. 2026 Apr 24. doi: 10.1038/s41386-026-02410.
   PubMed     Abstract available
   
   
   
9. HORNG JE, McCrea LT, Batorsky RE, Bowen JJ, et al
   Functional genomic profiling of schizophrenia-associated genes reveals key microglial regulators.
   Neuropsychopharmacology. 2026 Apr 16. doi: 10.1038/s41386-026-02406.
   PubMed     Abstract available
   
   
   
10. YANG BZ, He L, Liu TQ, Ma S, et al
    Causal links among gut microbiota, immune-inflammatory and compensatory immune-regulatory systems, and schizophrenia.
    Neuropsychopharmacology. 2026 Apr 15. doi: 10.1038/s41386-026-02407.
    PubMed     Abstract available
    
    
    March 2026
11. QI G, Zhang Y, Wang YL, Anjum F, et al
    Putative glymphatic function and free water in schizophrenia: A 7T DTI study across psychosis stages.
    Neuropsychopharmacology. 2026 Mar 24. doi: 10.1038/s41386-026-02391.
    PubMed     Abstract available
    
    
    February 2026
12. ONWORDI EC, Whitehurst T, Shatalina E, Mansur A, et al
    Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [(11)C]UCB-J positron emission tomography study.
    Neuropsychopharmacology. 2026 Feb 3. doi: 10.1038/s41386-026-02349.
    PubMed     Abstract available
    
    
    January 2026
13. HE Z, He W, Chen Z, Wei W, et al
    Intrinsic connectivity patterns of striatal subfields predict individual dimensions of psychopathology and are associated with cholinergic and serotonergic neurotransmission in schizophrenia.
    Neuropsychopharmacology. 2026 Jan 17. doi: 10.1038/s41386-026-02354.
    PubMed     Abstract available
    
    
    
14. ASIM A, Yang Y, Heilbronner U, Schulze T, et al
    The impact of collider bias on genetic prediction in psychotic disorders.
    Neuropsychopharmacology. 2026;51:430-439.
    PubMed     Abstract available
    
    
    December 2025
15. HAZLETT EA, Fiore VG, Shafritz KM, Ng S, et al
    Aberrant effective connectivity during working memory performance in schizotypal personality disorder and schizophrenia: A spectrum approach.
    Neuropsychopharmacology. 2025 Dec 11. doi: 10.1038/s41386-025-02295.
    PubMed     Abstract available
    
    
    November 2025
16. TARUMI R, Honda S, Cassidy C, Etani T, et al
    Associations of neuromelanin in the substantia nigra with antipsychotic response in schizophrenia.
    Neuropsychopharmacology. 2025 Nov 7. doi: 10.1038/s41386-025-02275.
    PubMed     Abstract available
    
    
    October 2025
17. O'BRIEN KJ, Huque ZM, Pike MR, Smith EC, et al
    Synergistic pathways to psychosis: understanding developmental risk and resilience factors.
    Neuropsychopharmacology. 2025 Oct 10. doi: 10.1038/s41386-025-02261.
    PubMed     Abstract available
    
    
    
18. CHATTERJEE S, Soria M, Norville ZC, Thompson KR, et al
    Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M(1) and M(4) receptors.
    Neuropsychopharmacology. 2025 Oct 4. doi: 10.1038/s41386-025-02256.
    PubMed     Abstract available
    
    
    September 2025
19. GARCIA-CERRO S, Gomez-Garrido A, Soria FN, Loucera C, et al
    Clozapine induces perineuronal net remodeling in a developmental mouse model exhibiting schizophrenia-relevant phenotypes.
    Neuropsychopharmacology. 2025 Sep 25. doi: 10.1038/s41386-025-02210.
    PubMed     Abstract available
    
    
    
20. GIRGIS RR, de la Fuente-Sandoval C, Lewis-Fernandez R, Reyes-Madrigal F, et al
    Concerted elevations of cortical and striatal glutamate and GABA in antipsychotic-free individuals at clinical high-risk for psychosis.
    Neuropsychopharmacology. 2025 Sep 25. doi: 10.1038/s41386-025-02251.
    PubMed     Abstract available
    
    
    
21. HERMS EN, Wisner KM
    Moving from isolation to integration: a Bayesian multisensory perspective of interoception and psychosis.
    Neuropsychopharmacology. 2025 Sep 24. doi: 10.1038/s41386-025-02250.
    PubMed    
    
    
    
22. HOLMES DR
    From psychosis to creativity: a lived experience perspective on serious mental illness symptoms.
    Neuropsychopharmacology. 2025 Sep 10. doi: 10.1038/s41386-025-02212.
    PubMed    
    
    
    August 2025
23. BERSHAD AK
    For those with schizophrenia, does cannabidiol make cannabis use safer?
    Neuropsychopharmacology. 2025 Aug 26. doi: 10.1038/s41386-025-02199.
    PubMed    
    
    
    
24. ANKEETA A, Tripathi A, Pillai B, Ma Y, et al
    Blood and neuronal extracellular vesicle mitochondrial disruptions in schizophrenia.
    Neuropsychopharmacology. 2025 Aug 23. doi: 10.1038/s41386-025-02204.
    PubMed     Abstract available
    
    
    
25. KU BS, Young JW
    Social environment as a determinant of mismatch negativity in early psychosis.
    Neuropsychopharmacology. 2025 Aug 19. doi: 10.1038/s41386-025-02195.
    PubMed    
    
    
    
26. FERLAND JN, Di Forti M
    Rewired realities: novel insights into the neurobiology of cannabis use disorder and psychosis.
    Neuropsychopharmacology. 2025 Aug 6. doi: 10.1038/s41386-025-02189.
    PubMed    
    
    
    
27. ULIANA DL, Walsh RA, Fabris D, Grace AA, et al
    Evenamide reverses schizophrenia-related dysfunction in a neurodevelopmental animal model.
    Neuropsychopharmacology. 2025 Aug 5. doi: 10.1038/s41386-025-02188.
    PubMed     Abstract available
    
    
    July 2025
28. CHESNEY E, Oliver D, Sarma A, Lamper AD, et al
    Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.
    Neuropsychopharmacology. 2025 Jul 24. doi: 10.1038/s41386-025-02175.
    PubMed     Abstract available
    
    
    
29. KAWATAKE-KUNO A, Leventhal MB, Morishita H
    Impact of early social isolation on social circuits and behavior: relevance to schizophrenia.
    Neuropsychopharmacology. 2025 Jul 4. doi: 10.1038/s41386-025-02156.
    PubMed     Abstract available
    
    
    May 2025
30. HUANG H, Wang X, Qin X, Xu R, et al
    Distinct structural deficits in treatment-resistant schizophrenia and their putative neurotransmitter basis: a source-based morphometry analysis.
    Neuropsychopharmacology. 2025 May 28. doi: 10.1038/s41386-025-02135.
    PubMed     Abstract available
    
    
    
31. KING VL, Hellemann G, Lahti AC, Defenderfer M, et al
    Cortical myelin mapping in antipsychotic medication-naive, first-episode psychosis patients.
    Neuropsychopharmacology. 2025 May 23. doi: 10.1038/s41386-025-02137.
    PubMed     Abstract available
    
    
    April 2025
32. GOLDSMITH DR, Ning CS, Strauss GP, Gross RE, et al
    Inflammation is associated with avolition and reduced resting state functional connectivity in corticostriatal reward circuitry in patients with schizophrenia.
    Neuropsychopharmacology. 2025 Apr 24. doi: 10.1038/s41386-025-02114.
    PubMed     Abstract available
    
    
    
33. KU BS, Hamilton H, Yuan Q, Parker DA, et al
    Neighborhood social fragmentation in relation to impaired mismatch negativity among youth at clinical high risk for psychosis and healthy comparisons.
    Neuropsychopharmacology. 2025 Apr 2. doi: 10.1038/s41386-025-02093.
    PubMed     Abstract available
    
    
    March 2025
34. DHAMALA E, Rubio JM
    Persistent brain network signatures in psychosis: implications for diagnosis, prognosis, and treatment.
    Neuropsychopharmacology. 2025 Mar 5. doi: 10.1038/s41386-025-02079.
    PubMed    
    
    
    February 2025
35. DYBOWSKI FP, Scott DS, Tamminga CA
    Pharmacological reduction of reverse-translated hippocampal hyperactivity in mouse: relevance for psychosis.
    Neuropsychopharmacology. 2025 Feb 27. doi: 10.1038/s41386-025-02077.
    PubMed     Abstract available
    
    
    
36. FOSTER ML, Ye J, Powers AR, Dvornek NC, et al
    Connectome-based predictive modeling of early and chronic psychosis symptoms.
    Neuropsychopharmacology. 2025 Feb 27. doi: 10.1038/s41386-025-02064.
    PubMed     Abstract available
    
    
    
37. SAMSOM JN, Xu M, Avila A, Daskalakis AA, et al
    Protein interacting with C-kinase 1 (PICK1) regulates synaptic function and reversal learning in a mouse model for schizophrenia.
    Neuropsychopharmacology. 2025 Feb 22. doi: 10.1038/s41386-025-02072.
    PubMed     Abstract available
    
    
    November 2024
38. ZHANG W, Wang L, Wu X, Yao L, et al
    Improved patient identification by incorporating symptom severity in deep learning using neuroanatomic images in first episode schizophrenia.
    Neuropsychopharmacology. 2024 Nov 6. doi: 10.1038/s41386-024-02021.
    PubMed     Abstract available
    
    
    September 2024
39. BRAKATSELOS C, Polissidis A, Ntoulas G, Asprogerakas MZ, et al
    Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.
    Neuropsychopharmacology. 2024 Sep 6. doi: 10.1038/s41386-024-01977.
    PubMed     Abstract available
    
    
    August 2024
40. SLIFSTEIN M, Qu W, Gil R, Weinstein JJ, et al
    Kappa opioid receptor availability predicts severity of anhedonia in schizophrenia.
    Neuropsychopharmacology. 2024 Aug 31. doi: 10.1038/s41386-024-01975.
    PubMed     Abstract available
    
    
    July 2024
41. ABRAM SV, Hua JPY
    Pons connectivity correlates with neurophysiological and clinical signatures of predictive coding in psychosis.
    Neuropsychopharmacology. 2024 Jul 22. doi: 10.1038/s41386-024-01919.
    PubMed    
    
    
    
42. SMUCNY J, Carter CS
    Is treatment-resistant schizophrenia a neuroimmune condition? Meta-analytic evidence from magnetic resonance spectroscopy.
    Neuropsychopharmacology. 2024 Jul 18. doi: 10.1038/s41386-024-01932.
    PubMed    
    
    
    June 2024
43. JOHNSON EC, Austin-Zimmerman I, Thorpe HHA, Levey DF, et al
    Cross-ancestry genetic investigation of schizophrenia, cannabis use disorder, and tobacco smoking.
    Neuropsychopharmacology. 2024 Jun 21. doi: 10.1038/s41386-024-01886.
    PubMed     Abstract available
    
    
    
44. CHENOWETH MJ
    Cracking the chicken and egg problem of schizophrenia and substance use: Genetic interplay between schizophrenia, cannabis use disorder, and tobacco smoking.
    Neuropsychopharmacology. 2024 Jun 11. doi: 10.1038/s41386-024-01898.
    PubMed    
    
    
    
45. KOCH E, Kampe A, Alver M, Siguretharson S, et al
    Polygenic liability for antipsychotic dosage and polypharmacy - a real-world registry and biobank study.
    Neuropsychopharmacology. 2024;49:1113-1119.
    PubMed     Abstract available
    
    
    May 2024
46. PISANU C, Congiu D, Meloni A, Paribello P, et al
    Dissecting the genetic overlap between severe mental disorders and markers of cellular aging: Identification of pleiotropic genes and druggable targets.
    Neuropsychopharmacology. 2024;49:1033-1041.
    PubMed     Abstract available
    
    
    April 2024
47. LIVINGSTON NR, Kiemes A, Devenyi GA, Knight S, et al
    Effects of diazepam on hippocampal blood flow in people at clinical high risk for psychosis.
    Neuropsychopharmacology. 2024 Apr 24. doi: 10.1038/s41386-024-01864.
    PubMed     Abstract available
    
    
    March 2024
48. SCHOONOVER KE, Dienel SJ, Holly Bazmi H, Enwright JF 3rd, et al
    Altered excitatory and inhibitory ionotropic receptor subunit expression in the cortical visuospatial working memory network in schizophrenia.
    Neuropsychopharmacology. 2024 Mar 28. doi: 10.1038/s41386-024-01854.
    PubMed     Abstract available
    
    
    
49. HUANG AS, Kang K, Vandekar S, Rogers BP, et al
    Lifespan development of thalamic nuclei and characterizing thalamic nuclei abnormalities in schizophrenia using normative modeling.
    Neuropsychopharmacology. 2024 Mar 13. doi: 10.1038/s41386-024-01837.
    PubMed     Abstract available
    
    
    
50. SEITZ-HOLLAND J, Aleman-Gomez Y, Cho KIK, Pasternak O, et al
    Matrix metalloproteinase 9 (MMP-9) activity, hippocampal extracellular free water, and cognitive deficits are associated with each other in early phase psychosis.
    Neuropsychopharmacology. 2024 Mar 2. doi: 10.1038/s41386-024-01814.
    PubMed     Abstract available
    
    
    February 2024
51. CABRERA-MENDOZA B, Aydin N, Fries GR, Docherty AR, et al
    Estimating the direct effects of the genetic liabilities to bipolar disorder, schizophrenia, and behavioral traits on suicide attempt using a multivariable Mendelian randomization approach.
    Neuropsychopharmacology. 2024 Feb 23. doi: 10.1038/s41386-024-01833.
    PubMed     Abstract available
    
    
    
52. TRUONG TTT, Liu ZSJ, Panizzutti B, Kim JH, et al
    Network-based drug repurposing for schizophrenia.
    Neuropsychopharmacology. 2024 Feb 6. doi: 10.1038/s41386-024-01805.
    PubMed     Abstract available
    
    
    January 2024
53. PAUL SM, Potter WZ
    Finding new and better treatments for psychiatric disorders.
    Neuropsychopharmacology. 2024;49:3-9.
    PubMed     Abstract available
    
    
    
54. HANSON JE, Yuan H, Perszyk RE, Banke TG, et al
    Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.
    Neuropsychopharmacology. 2024;49:51-66.
    PubMed     Abstract available
    
    
    December 2023
55. ARIME Y, Saitoh Y, Ishikawa M, Kamiyoshihara C, et al
    Activation of prefrontal parvalbumin interneurons ameliorates working memory deficit even under clinically comparable antipsychotic treatment in a mouse model of schizophrenia.
    Neuropsychopharmacology. 2023 Dec 4. doi: 10.1038/s41386-023-01769.
    PubMed     Abstract available
    
    
    October 2023
56. WANG DM, Chen DC, Xiu MH, Wang L, et al
    A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naive first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms.
    Neuropsychopharmacology. 2023 Oct 30. doi: 10.1038/s41386-023-01760.
    PubMed     Abstract available
    
    
    
57. ROESKE MJ, McHugo M, Rogers B, Armstrong K, et al
    Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial.
    Neuropsychopharmacology. 2023 Oct 13. doi: 10.1038/s41386-023-01730.
    PubMed     Abstract available
    
    
    September 2023
58. FAN L, Liang L, Wang Y, Ma X, et al
    Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex.
    Neuropsychopharmacology. 2023 Sep 26. doi: 10.1038/s41386-023-01741.
    PubMed     Abstract available
    
    
    
59. ZHOU DY, Su X, Wu Y, Yang Y, et al
    Decreased CNNM2 expression in prefrontal cortex affects sensorimotor gating function, cognition, dendritic spine morphogenesis and risk of schizophrenia.
    Neuropsychopharmacology. 2023 Sep 15. doi: 10.1038/s41386-023-01732.
    PubMed     Abstract available
    
    
    
60. RABIN RA, Palaniyappan L
    Brain health in ethnically minority youth at risk for psychosis.
    Neuropsychopharmacology. 2023 Sep 4. doi: 10.1038/s41386-023-01719.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum